<DOC>
	<DOCNO>NCT02483325</DOCNO>
	<brief_summary>Determine efficiency myéloablative conditioning associate Fludarabine , Thymoglobuline , intravenous Busulfan adapt dose , accord pharmacokinetics realize first day administration ( J-6 conditioning ) busulfan , preparation allogenic transplant family family compatible HLA .</brief_summary>
	<brief_title>Study Evaluating Efficacy Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous ( Busilvex® ) Patients High Risk Carrying Blood Diseases</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Inclusion Criteria : Informed consent sign , Patient affiliate social security system benefit system , Related HLA identical donor unrelated HLA identical donor : patient age &gt; 55 year hematological malignancy deem eligible allogeneic transplant genoidentical donor phenoidentical 10/10 basic pathology consider `` chemosensitive '' complete partial remission ( CR , PR ) stable disease Exclusion Criteria : Pregnant lactate woman without contraception ( child bear potential woman ) Patient deprive liberty supervision guardian Impossibility undergo medical examination study geographical , social psychological reason Usual contraindication allogenic transplant Aged &lt; 55 year History allogenic transplant Concomitant neoplastic disease Evolutive psychiatric disease HIV seropositivity C hepatitis treatment Women childbearing age man , absence effective contraception treatment 12 month treatment discontinuation</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>